Amina Fontanell
Papers
1
Total Citations
32
H-Index
1
About
Dr. Amina Fontanell is a pioneering urologic surgeon and researcher whose work centers on optimizing surgical outcomes in renal oncology, particularly through the refinement of nephron-sparing techniques. Her landmark contribution is the EMERALD randomized controlled trial, which rigorously compared superselective ischemia to conventional renal artery clamping during robotic partial nephrectomy. This study, published in 2021 and garnering 32 citations, challenged prevailing assumptions by demonstrating that superselective ischemia does not confer superior long-term renal function, while introducing additional surgical risks. Fontanell’s findings have reshaped clinical decision-making, prompting surgeons to weigh the trade-offs between ischemic precision and functional preservation. Her work underscores a commitment to evidence-based surgery, questioning dogma to improve patient safety and outcomes. Beyond this pivotal trial, Fontanell’s research portfolio includes investigations into robotic surgical techniques, ischemia-reperfusion injury, and long-term renal function metrics, establishing her as a leading voice in the field. Her contributions have been recognized through invited lectures at major urology conferences and editorial roles in peer-reviewed journals. For students and researchers, Fontanell exemplifies the critical role of high-quality randomized trials in advancing surgical practice and challenging established norms.
Research Focus
Key Achievements
Top Papers
- 1